Kepos Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Kepos Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,997	Closed	-$875K	–	313
2019 Q4	$875K	Buy	3,997 +1,199	+43%	+$243K	0.08%	153
2019 Q3	$474K	Sell	2,798 -3,290	-54%	-$582K	0.05%	201
2019 Q2	$1.12M	Buy	+6,088	New	+$1.06M	0.11%	161
2018 Q4	–	Sell	-24,513	Closed	-$4.72M	–	410
2018 Q3	$4.72M	Sell	24,513 -9,081	-27%	-$1.62M	0.24%	99
2018 Q2	$5.71M	Buy	33,594 +22,198	+195%	+$3.44M	0.29%	81
2018 Q1	$1.86M	Sell	11,396 -301	-3%	-$49.2K	0.11%	141
2017 Q4	$1.75M	Buy	+11,697	New	+$1.73M	0.16%	124

Other funds holding VRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Kepos Capital's VRTX Position: Q1 2020 in Review

Kepos Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2020, closing a stake of 3,997 shares — an estimated $875K sold.

Kepos Capital first reported a position in VRTX in Q4 2017 and held it in 7 quarters. The position peaked at $5.71M in Q2 2018. 855 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

Kepos Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Kepos Capital sold 3,997 Vertex Pharmaceuticals shares in Q1 2020, an estimated $875K.
Kepos Capital first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Kepos Capital's Vertex Pharmaceuticals position peaked at $5.71M in Q2 2018.
855 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.